


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Original) A compound of Formula (I):



wherein:

R₁ is H or C₁₋₈ alkyl;
R₂ is C₁₋₄ alkyl, -CH₂-O-C₁₋₄ alkyl, C₁₋₄ haloalkyl or CH₂OH; and
R₃, R₄, R₅ and R₆ are each independently H, C₁₋₄ alkyl, amino, cyano, halogen, C₁₋₄ haloalkyl, nitro or OH; or
a pharmaceutically acceptable salt, hydrate and solvate thereof;
provided that when R₂ is C₁₋₄ alkyl, -CH₂-O-C₁₋₄ alkyl, and CH₂OH then R₃ and R₆ are not both hydrogen.

2. (Original) The compound according to claim 1 wherein R₁ is H.
3. (Original) The compound according to claim 1 wherein R₁ is C₁₋₈ alkyl.
- 4-8. (Canceled)

9. (Currently amended) The compound according to ~~any one of claims~~ claim 1 to 8 wherein R₂ is C₁₋₄ alkyl.

10. (Currently amended) The compound according to ~~any one of claims~~ claim 1 to 8 wherein R₂ is methyl.

11-13. (Canceled)

14. (Currently amended) The compound according to ~~any one of claims~~ claim 1 to 8 wherein R₂ is C₁₋₄ haloalkyl.

15. (Canceled)

16. (Currently amended) The compound according to ~~any one of claims~~ claim 1 to 15 wherein R₃ is H.

17. (Currently amended) The compound according to ~~any one of claims~~ claim 1 to 15 wherein R₃ is C₁₋₄ alkyl.

18-20. (Canceled)

21. (Currently amended) The compound according to ~~any one of claims~~ claim 1 to 15 wherein R₃ is halogen.

22-25. (Canceled)

26. (Currently amended) The compound according to ~~any one of claims~~ claim 1 to 15 wherein R₃ is C₁₋₄ haloalkyl.

27-29. (Canceled)

30. (Currently amended) The compound according to ~~any one of claims~~ claim 1 to 29 wherein R₄ is H.

31. (Currently amended) The compound according to ~~any one of claims~~ claim 1 to 29 wherein R₄ is C₁₋₄ alkyl.

32-34. (Canceled)

35. (Currently amended) The compound according to ~~any one of claims~~ claim 1 to 29 wherein R₄ is halogen.

36-39. (Canceled)

40. (Currently amended) The compound according to ~~any one of claims~~ claim 1 to 29 wherein R₄ is C₁₋₄ haloalkyl.

41-43. (Canceled)

44. (Currently amended) The compound according to ~~any one of claims~~ claim 1 to 43 wherein R₅ is H.

45. (Currently amended) The compound according to ~~any one of claims~~ claim 1 to 43 wherein R₅ is C₁₋₄ alkyl.

46-48. (Canceled)

49. (Currently amended) The compound according to ~~any one of claims~~ claim 1 to 43 wherein R₅ is halogen.

50-53. (Canceled)

54. (Currently amended) The compound according to ~~any one of claims~~ claim 1 to 43 wherein R₅ is C₁₋₄ haloalkyl.

55-57. (Canceled)

58. (Currently amended) The compound according to ~~any one of claims~~ claim 1 to 57 wherein R₆ is H.

59. (Currently amended) The compound according to ~~any one of claims~~ claim 1 to 57 wherein R₆ is C₁₋₄ alkyl.

60-62. (Canceled)

63. (Currently amended) The compound according to ~~any one of claims~~ claim 1 to 57 wherein R₆ is halogen.

64-67. (Canceled)

68. (Currently amended) The compound according to ~~any one of claims~~ claim 1 to 57 wherein R₆ is C₁₋₄ haloalkyl.

69-71. (Canceled)

72. (Original) The compound of claim 1 selected from the group consisting of:

6,8-Dichloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

6-Chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

8-Chloro-9-fluoro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; and

8,9-Dichloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine.

73. (Original) The compound of claim 1 that is 9-bromo-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine.

74. (Original) The compound of claim 1 selected from the group consisting of:

N-methyl-8,9-dichloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; and

N-methyl-9-bromo-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine.

75. (Currently amended) The compound according to ~~any one of claims~~ claim 1 to 74 wherein said compound is an *R* enantiomer.

76. (Currently amended) The compound according to ~~any one of claims~~ claim 1 to 74 wherein said compound is an *S* enantiomer.

77. (Currently amended) A pharmaceutical composition comprising a compound according to ~~any one of claims~~ claim 1 to 76 and a pharmaceutically acceptable carrier.

78. (Currently amended) A method of modulating a 5HT_{2C} receptor comprising contacting said receptor with a therapeutically effective amount of a compound according to ~~any one of claims~~ claim 1 to 76.

79. (Original) The method according to claim 78 wherein said compound is an agonist of said receptor.

80. (Currently amended) A method of prophylaxis or treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus or sleep apnea comprising administering to an individual in need of such prophylaxis or treatment a therapeutically effective amount of a compound according to ~~any one of claims~~ claim 1 to 76 or a pharmaceutical composition according to claim 77.

81. (Original) The method according to claim 80 wherein the disorders of the central nervous system are selected the group consisting of depression, atypical depression, bipolar disorders, anxiety disorders, obsessive-compulsive disorders, social phobias or panic states, sleep disorders, sexual dysfunction, psychoses, schizophrenia, migraine and other conditions associated with cephalic pain or other pain, raised intracranial pressure, epilepsy, personality disorders, Alzheimer disease, age-related behavioral disorders, behavioral disorders associated with dementia, organic mental disorders, mental disorders in childhood, aggressivity, age-related memory disorders, chronic fatigue syndrome, drug and alcohol addiction, obesity, bulimia, anorexia nervosa and premenstrual tension.

82. (Original) The method according to claim 81 wherein the disorder of the central nervous system is obesity.

83. (Canceled)

84. (Original) The method according to claim 81 wherein the sexual dysfunction is Male erectile dysfunction.

85-89. (Canceled)

90. (Currently amended) The method according to claim ~~89~~82 or 84 wherein said ~~mammal~~individual is a human.

91. (Currently amended) A method of decreasing food intake of an individual comprising administering to said individual a therapeutically effective amount of a compound according to ~~any one of claims~~claim ~~1 to 76~~ or a pharmaceutical composition according to claim 77.

92. (Canceled)

93. (Currently amended) The method according to claim ~~92~~91 wherein said ~~mammal~~individual is a human.

94. (Currently amended) A method of inducing satiety in an individual comprising administering to said individual a therapeutically effective amount of a compound according to ~~any one of claims~~claim ~~1 to 76~~ or a pharmaceutical composition according to claim 77.

95. (Canceled)

96. (Currently amended) The method according to claim ~~95~~94 wherein said ~~mammal~~individual is a human.

97. (Currently amended) A method of controlling weight gain of an individual comprising administering to said individual suffering from weight control a therapeutically effective amount of a compound according to ~~any one of claims~~claim ~~1 to 76~~ or a pharmaceutical composition according to claim 77.

98. (Canceled)

99. (Currently amended) The method according to claim ~~98~~97 wherein said ~~mammal~~ individual is a human.

100-103. (Canceled)

104. (Currently amended) A method of producing a pharmaceutical composition comprising admixing at least one compound according to ~~any one of claims claim 1 to 76~~ claim 1 to 76 and a pharmaceutically acceptable carrier.

105-123. (Canceled)

124. (New) The compound according to claim 1 wherein:

R₁ is H, methyl, ethyl, *n*-propyl, *iso*-propyl or *n*-butyl;

R₂ is methyl, ethyl, *iso*-propyl, *n*-butyl or -CF₃;

R₃ is H, -CH₃, amino, cyano, fluorine atom, chlorine atom, bromine atom, iodine atom, CF₃, nitro or -OH;

R₄ is H, -CH₃, amino, cyano, fluorine atom, chlorine atom, bromine atom, iodine atom, CF₃, nitro or -OH;

R₅ is H, -CH₃, amino, cyano, fluorine atom, chlorine atom, bromine atom, iodine atom, CF₃, nitro or -OH; and

R₆ is H, -CH₃, amino, cyano, fluorine atom, chlorine atom, bromine atom, iodine atom, CF₃, nitro or -OH.

125. (New) A method of treating a 5HT_{2C} receptor associated disorder comprising administering to an individual in need of such treatment an effective amount of a compound according to claim 1, or a pharmaceutical composition according to claim 77.